74716-96-4Relevant academic research and scientific papers
OXYTOCIN DERIVATIVES WITH IMPROVED PROPERTIES
-
Paragraph 0055; 0065, (2021/06/26)
The present invention provides novel oxytocin derivative compounds that contain a fatty acid moiety that is conjugated to a modified oxytocin scaffold. The oxytocin derivative compounds of the invention are potent oxytocin agonists with substantially improved stability. Also provided in the invention are therapeutic methods of using the compounds in the treatment of various diseases, e.g., metabolic disorders such as obesity.
Alkyl-Aryl-Vancomycins: Multimodal Glycopeptides with Weak Dependence on the Bacterial Metabolic State
Sarkar, Paramita,Basak, Debajyoti,Mukherjee, Riya,Bandow, Julia E.,Haldar, Jayanta
, p. 10185 - 10202 (2021/07/28)
Resistance to last-resort antibiotics such as vancomycin for Gram-positive bacterial infections necessitates the development of new therapeutics. Furthermore, the ability of bacteria to survive antibiotic therapy through formation of biofilms and persiste
MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
-
Paragraph 0336, (2016/10/04)
Methods and compositions are provided for extending the half-life of a therapeutic agent. One half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents comprising a half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.
MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
-
Paragraph 0492; 0493, (2015/03/28)
Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.
Amphiphilic EuDOTA-tetraamide complexes form micelles with enhanced CEST sensitivity
Evbuomwan, Osasere M.,Kiefer, Garry,Sherry, A. Dean
experimental part, p. 2126 - 2134 (2012/06/15)
The synthesis and characterization of four new DOTA-tetraamide ligands having variable alkyl chain lengths (C1, C12, C 14, and C16) and their respective europium(III) complexes are reported. The three EuL comple
